Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology
company focused on developing therapeutic and diagnostic products
for neurological disorders and orphan indications, announced that
data from the Phase 1/2a clinical study of eltoprazine for the
treatment of Parkinson's disease levodopa-induced dyskinesia
(PD-LID) has been accepted for presentation at the 19th
International Congress of Parkinson's Disease and Movement
Disorders being held June 14-18, 2015, in San Diego, CA.
Professor Per Svenningsson, M.D., Ph.D., of the Centre for
Molecular Medicine at Karolinska Institutet, will present poster
number 331 entitled, "Single oral treatment with the 5-HT1A/B
agonist, Eltoprazine, counteracts L-dopa-induced dyskinesias in
Parkinson's disease: A phase I/IIA, double-blind, randomized,
placebo-controlled, dose-finding study," on Monday, June 15, 2015,
from 12:30-2:00 p.m. PDT in the Coronado Ballroom of the Manchester
Grand Hyatt.
Further, poster number 331 has been selected for a guided poster
tour with Professor Svenningsson. Guided Poster Tour 16 entitled,
"Parkinson's Disease: Neuropharmacology," will be held at
Harbor G, 2nd Level, Harbor Tower from 12:00-3:30 p.m. PDT on
Thursday, June 18, 2015.
Eltoprazine is a small-molecule 5-HT1A/1B serotonin
receptor agonist, investigational drug candidate, with a
well-established safety profile. A Phase 1/2a dose-finding study
was conducted with eltoprazine to determine its effect against
levodopa-induced dyskinesia, in patients with Parkinson's disease.
The double-blind, randomized, placebo-controlled clinical study was
led by Professor Svenningsson, Professor Anders Björklund, Ph.D.,
Faculty of Medicine at Lund University, and Professor Håkan Widner,
M.D., Ph.D., Faculty of Medicine at Lund University. The study was
partially supported by a grant from The Michael J. Fox
Foundation for Parkinson's Research.
Amarantus previously announced that it will commence a
multi-center, 60-subject Phase 2b study in individuals with PD-LID
before the end of the June 2015. The study will be a
double-blind, placebo-controlled, four-way crossover, dose range
finding, clinical trial designed to evaluate dose response effect
of repeated eltoprazine dosing on safety, tolerability and
dyskinesia severity using state-of-the-art rating scales, diaries
and motion sensors (ClinicalTrials.gov Identifier: NCT02439125).
Pharmacokinetics and pharmacodynamics will also be evaluated. The
Company expects to report top-line results from this Phase 2b study
in the second quarter of 2016.
About Eltoprazine
Eltoprazine is a small molecule 5HT1A/1B partial agonist in
clinical development for the treatment of Parkinson's disease
levodopa-induced dyskinesia (PD-LID) and adult attention deficit
hyperactivity disorder (ADHD). Eltoprazine has been evaluated in
over 680 human subjects to date, and has a well-established safety
profile. Eltoprazine was originally developed by Solvay
Pharmaceuticals for the treatment of aggression. Upon Solvay's
merger with Abbott Pharmaceuticals, the eltoprazine program was
out-licensed to PsychoGenics. PsychoGenics licensed eltoprazine to
Amarantus following successful proof-of-concept trials in PD-LID
and adult ADHD.
About Parkinson's Disease and Levodopa-Induced
Dyskinesia (PD-LID)
Parkinson's disease is a chronic, progressive neurodegenerative
disorder that causes motor symptoms such as tremors, rigidity and
slowed movements as well as non-motor symptoms including cognitive
impairment, mood disorders and autonomic dysfunction. The
Parkinson's Disease Foundation estimates that there are
approximately one million people living with Parkinson's disease in
the United States and seven to 10 million PD patients worldwide.
The most commonly prescribed treatments for Parkinson's disease are
levodopa-based therapies. In the body, levodopa is converted to
dopamine to replace the dopamine loss caused by the disease. As
dopamine neurons in the brain are lost the therapeutic efficacy of
levodopa attenuates, and increased use is associated with a side
effect of dyskinesias. These are involuntary, uncontrollable and
often exaggerated and jerky movements. They are distinct from the
static, rhythmic tremor as a symptom of Parkinson's disease.
Levodopa-induced dyskinesia can be severely disabling, rendering
patients unable to perform routine daily tasks.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases in the areas of
neurology, psychiatry, ophthalmology and regenerative medicine.
AMBS' Therapeutics division has development rights to eltoprazine,
a Phase 2b ready small molecule indicated for Parkinson's disease
levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression,
and owns the intellectual property rights to a therapeutic protein
known as mesencephalic-astrocyte-derived neurotrophic factor (MANF)
and is developing MANF-based products as treatments for brain and
ophthalmic disorders. AMBS' Diagnostics division owns the rights to
MSPrecise®, a proprietary next-generation DNA sequencing (NGS)
assay for the identification of patients with relapsing-remitting
multiple sclerosis (RRMS) at first clinical presentation, has an
exclusive worldwide license to the Lymphocyte Proliferation test
(LymPro Test®) for Alzheimer's disease, which was developed by
Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and
owns intellectual property for the diagnosis of Parkinson's disease
(NuroPro). AMBS also owns the discovery of neurotrophic factors
(PhenoGuard™) that led to MANF's discovery.
For further information please visit www.Amarantus.com, or
connect with the Company on Facebook, LinkedIn, Twitter and
Google+.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Sep 2023 to Sep 2024